Videos

The panel closes by highlighting unmet needs in molecular testing, and advances they are looking forward to.

The Future of Molecular Testing in NSCLC

Drs Morganstein and Ramkumar detail the financial considerations patients and physicians face during the process of molecular testing for NSCLC.

Financial Considerations with Molecular Testing for Patients With NSCLC

Bhuvana Ramkumar, MD, and Neil Morganstein, MD, share if they believe there should be a standard for molecular testing reports, and how frequently they communicate with their patients during the process.

Receiving Molecular Testing Results for NSCLC

The panel reflects on challenges with the EMR, and the impact it has on treatment decision making for their patients with NSCLC.

Integrating Molecular Testing Results into Electronic Medical Records

Bhuvana Ramkumar, MD, highlights the strengths of liquid biopsy for molecular testing in NSCLC.

Using Liquid Biopsy for Molecular Testing in NSCLC

Experts discuss the types of genotype panels they often use for testing patients with NSCLC, and why.

Types of Tissue Next-Generation Sequencing Platforms in NSCLC

Dr Neil Morganstein explains the typical turnaround times for molecular testing he sees and the challenges that prolong the process.

Average Turnaround Time for NSCLC Molecular Testing

Dr Bhuvana Ramkumar shares best practices for molecular testing in NSCLC to obtain the most accurate results.

Best Practices for Accurate Tissue Genotyping in NSCLC

Bhuvana Ramkumar, MD, and Neil Morganstein, MD, share standards of communication among the care team at their clinical practice sites.

Enhancing Communication Among the Multidisciplinary Care Team

Drs Benjamin Levy, Neil Morganstein, and Bhuvana Ramkumar discuss challenges of procuring for molecular testing in patients with NSCLC.

Challenges With and Strategies for Tissue Procurement in NSCLC

Neil Morganstein, MD, head and neck cancer medical oncologist, Overlook Medical Center’s Carol G. Simon Cancer Center, Atlantic Health System, discusses the mechanism of action of lurbinectedin (Zepzelca) in metastatic small cell lung cancer (SCLC).

In June 2020, the FDA granted an accelerated approved to lurbinectedin for the treatment of patients with metastatic SCLC with disease progression following platinum-based chemotherapy. 

Lurbinectedin is a unique molecule that was derived from 

, a species of sea squirts, says Morganstein. The molecule intercalates into the DNA and inhibits DNA synthesis, Morganstein adds.

The FDA approval of the agent marks a significant milestone in the treatment of patients with SCLC, says Morganstein. Other effective medications were not approved because they did not meet the requirements needed for FDA approval, Morganstein adds. Notably, lurbinectedin was added as a preferred second-line standard for this patient population in the National Comprehensive Cancer Network guidelines, concludes Morganstein.

Neil Morganstein, MD, discusses the mechanism of action of lurbinectedin in metastatic small cell lung cancer. 



Neil Morganstein, MD

Articles